aetherAI Co., Ltd. (7803)

Overview

aetherAI Co., Ltd. is a technology company based in Taiwan, focusing on the development of digital pathology platforms and artificial intelligence-assisted diagnosis systems tailored for medical imaging. The company primarily caters to medical institutions, biotech firms, and pharmaceutical companies, striving to enhance pathological diagnostics by integrating advanced AI technologies into clinical workflows. Since its inception in 2015, aetherAI has its headquarters in Taipei and has experienced significant growth, with its revenue rising from NT$37.6 million in 2022 to NT$102 million in 2023, demonstrating its increasing prominence in the global medical software and technology services sector within healthcare. The company has successfully expanded its sales across Taiwan, Japan, and Germany, establishing itself as a leader in the field.

Products and Services

• aetherSlide:

  This digital pathology imaging platform is designed for comprehensive image management and annotation. It facilitates the digitalization of pathology samples, allowing for efficient storage, retrieval, and analysis of medical images, significantly improving the workflow for pathologists.

• aetherAI Hema:

  A cutting-edge tool specifically developed for bone marrow smear analysis, aetherAI Hema employs deep learning algorithms to enhance the accuracy and efficiency of hematological diagnoses. This product streamlines the process of interpreting complex blood samples, reducing human error and improving patient outcomes.

• aetherAI Endo:

  This product focuses on the detection of endoscopic colorectal polyps, utilizing sophisticated AI techniques to identify anomalies in real-time during endoscopic procedures. By aiding healthcare professionals in the early detection of colorectal cancer, aetherAI Endo plays a crucial role in preventive diagnostics.

• aetherAI LDCT:

  Specializing in pulmonary nodule identification, aetherAI LDCT enhances imaging analysis through deep neural networks, improving the detection rate of potential lung cancers. This tool empowers radiologists with advanced diagnostic capabilities, supporting timely and effective treatment decisions.